Hemab Therapeutics closed a $157 million financing to advance a portfolio of coagulation‑disorder programs, including a sutacimig pivotal trial planned for Glanzmann thrombasthenia and an early‑stage antibody program showing proof‑of‑mechanism. The round was led by Sofinnova Partners with participation from crossover and strategic investors. Management said the funds will support pivotal initiation and continued development across multiple rare‑bleeding indications where commercial incentives have lagged despite clear unmet need. Hemab positioned the raise as a step toward creating a focused company addressing underserved coagulation diseases. Investors and analysts flagged the financing as a sign that specialty rare‑disease biotech continues to attract capital when programs show clinical traction and clear regulatory pathways.